---
reference_id: "PMID:32997960"
title: MYC Promotes Bone Marrow Stem Cell Dysfunction in Fanconi Anemia.
authors:
- Rodríguez A
- Zhang K
- Färkkilä A
- Filiatrault J
- Yang C
- Velázquez M
- Furutani E
- Goldman DC
- García de Teresa B
- Garza-Mayén G
- McQueen K
- Sambel LA
- Molina B
- Torres L
- González M
- Vadillo E
- Pelayo R
- Fleming WH
- Grompe M
- Shimamura A
- Hautaniemi S
- Greenberger J
- Frías S
- Parmar K
- "D'Andrea AD"
journal: Cell Stem Cell
year: '2021'
doi: 10.1016/j.stem.2020.09.004
content_type: abstract_only
---

# MYC Promotes Bone Marrow Stem Cell Dysfunction in Fanconi Anemia.
**Authors:** Rodríguez A, Zhang K, Färkkilä A, Filiatrault J, Yang C, Velázquez M, Furutani E, Goldman DC, García de Teresa B, Garza-Mayén G, McQueen K, Sambel LA, Molina B, Torres L, González M, Vadillo E, Pelayo R, Fleming WH, Grompe M, Shimamura A, Hautaniemi S, Greenberger J, Frías S, Parmar K, D'Andrea AD
**Journal:** Cell Stem Cell (2021)
**DOI:** [10.1016/j.stem.2020.09.004](https://doi.org/10.1016/j.stem.2020.09.004)

## Content

1. Cell Stem Cell. 2021 Jan 7;28(1):33-47.e8. doi: 10.1016/j.stem.2020.09.004.
Epub  2020 Sep 29.

MYC Promotes Bone Marrow Stem Cell Dysfunction in Fanconi Anemia.

Rodríguez A(1), Zhang K(2), Färkkilä A(3), Filiatrault J(4), Yang C(4), 
Velázquez M(4), Furutani E(5), Goldman DC(6), García de Teresa B(7), Garza-Mayén 
G(7), McQueen K(4), Sambel LA(4), Molina B(7), Torres L(7), González M(7), 
Vadillo E(8), Pelayo R(9), Fleming WH(6), Grompe M(6), Shimamura A(5), 
Hautaniemi S(2), Greenberger J(10), Frías S(11), Parmar K(4), D'Andrea AD(12).

Author information:
(1)Department of Radiation Oncology and Center for DNA Damage and Repair, Dana 
Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; 
Laboratorio de Citogenética, Instituto Nacional de Pediatría, Mexico City 04530, 
Mexico.
(2)Research Program in Systems Oncology, Research Program Unit, Faculty of 
Medicine, University of Helsinki, Helsinki 00014, Finland.
(3)Department of Radiation Oncology and Center for DNA Damage and Repair, Dana 
Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Research 
Program in Systems Oncology, Research Program Unit, Faculty of Medicine, 
University of Helsinki, Helsinki 00014, Finland.
(4)Department of Radiation Oncology and Center for DNA Damage and Repair, Dana 
Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
(5)Dana Farber and Boston Children's Cancer and Blood Disorders Center, Harvard 
Medical School, Boston, MA 02115, USA.
(6)Oregon Stem Cell Center, Department of Pediatrics, Oregon Health and Science 
University, Portland, OR 97239, USA.
(7)Laboratorio de Citogenética, Instituto Nacional de Pediatría, Mexico City 
04530, Mexico.
(8)Unidad de Investigación Médica en Enfermedades Oncológicas, Hospital de 
Oncología, Centro Médico Nacional, Instituto Mexicano del Seguro Social, Mexico 
City 06720, Mexico.
(9)Centro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro 
Social, Puebla 74360, Mexico.
(10)Department of Radiation Oncology, University of Pittsburgh Medical Center, 
Pittsburgh, PA 15213, USA.
(11)Laboratorio de Citogenética, Instituto Nacional de Pediatría, Mexico City 
04530, Mexico; Instituto de Investigaciones Biomédicas, Universidad Nacional 
Autónoma de México, Mexico City 04510, Mexico.
(12)Department of Radiation Oncology and Center for DNA Damage and Repair, Dana 
Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA. 
Electronic address: alan_dandrea@dfci.harvard.edu.

Comment in
    Cell Stem Cell. 2021 Jan 7;28(1):8-9. doi: 10.1016/j.stem.2020.12.013.

Bone marrow failure (BMF) in Fanconi anemia (FA) patients results from 
dysfunctional hematopoietic stem and progenitor cells (HSPCs). To identify 
determinants of BMF, we performed single-cell transcriptome profiling of primary 
HSPCs from FA patients. In addition to overexpression of p53 and TGF-β pathway 
genes, we identified high levels of MYC expression. We correspondingly observed 
coexistence of distinct HSPC subpopulations expressing high levels of TP53 or 
MYC in FA bone marrow (BM). Inhibiting MYC expression with the BET bromodomain 
inhibitor (+)-JQ1 reduced the clonogenic potential of FA patient HSPCs but 
rescued physiological and genotoxic stress in HSPCs from FA mice, showing that 
MYC promotes proliferation while increasing DNA damage. MYC-high HSPCs showed 
significant downregulation of cell adhesion genes, consistent with enhanced 
egress of FA HSPCs from bone marrow to peripheral blood. We speculate that MYC 
overexpression impairs HSPC function in FA patients and contributes to 
exhaustion in FA bone marrow.

Copyright © 2020 Elsevier Inc. All rights reserved.

DOI: 10.1016/j.stem.2020.09.004
PMCID: PMC7796920
PMID: 32997960 [Indexed for MEDLINE]

Conflict of interest statement: Declaration of Interests The authors declare no 
competing interests.